In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results